The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance
Open accessAbstract
SUMMARY: There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse transcriptase (RT) inhibitors, and nonnucleoside RT inhibitors. HIV-1 resistance to these drugs is caused by mutations in the protease and RT enzymes, the molecular targets of these drugs. Drug resistance mutations arise most often in treated individuals, resulting from selective drug pressure in the presence of incompletely suppressed virus replication. HIV-1 isolates with drug resistance mutations, however, may also be transmitted to newly infected individuals. Three expert panels have recommended that HIV-1 protease and RT susceptibility testing should be used to help select HIV drug therapy. Although genotypic testing is more complex than typical antimicrobial susceptibility tests, there is a rich literature supporting the prognostic value of HIV-1 protease and RT mutations. This review describes the genetic mechanisms of HIV-1 drug resistance and summarizes published data linking individual RT and protease mutations to in vitro and in vivo resistance to the currently available HIV drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time
Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M., & Ho, D. D. (1996) · Science · doi:10.1126/science.271.5255.1582 · Cited by 3,531
Avoiding false positives with PCR
Kwok, S., & Higuchi, R. (1989) · Nature · doi:10.1038/339237a0 · Cited by 3,441
Viral dynamics in human immunodeficiency virus type 1 infection
Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., et al. (1995) · Nature · doi:10.1038/373117a0 · Cited by 3,260
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Wong, J. K., Hezareh, M., Günthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A., & Richman, D. D. (1997) · Science · doi:10.1126/science.278.5341.1291 · Cited by 2,186 · cited 1×
“If a patient once harbored drug-resistant variants, these variants may persist at low levels in latently infected cells even if a subsequent treatment regimen brings about complete virus suppression (103, 146, 163, 245, 411).”
BackgroundFinzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119 · cited 1×
“If a patient once harbored drug-resistant variants, these variants may persist at low levels in latently infected cells even if a subsequent treatment regimen brings about complete virus suppression (103, 146, 163, 245, 411).”
BackgroundHIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
Coffin, J. M. (1995) · Science · doi:10.1126/science.7824947 · Cited by 1,981
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914 · cited 1×
“(199) in which the RT is cocrystallized with nevirapine, which is displayed in space-fill mode.”
BackgroundHuang, H., Chopra, R., Verdine, G. L., & Harrison, S. C. (1998) · Science · doi:10.1126/science.282.5394.1669 · Cited by 1,420
Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)
Larder, B. A., & Kemp, S. D. (1989) · Science · doi:10.1126/science.2479983 · Cited by 1,163
Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Lu, X., Tantillo, C., Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., et al. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6320 · Cited by 1,115
Timing the ancestor of the HIV-1 pandemic strains.
Korber, B., Muldoon, M., Theiler, J., Gao, F., Gupta, R., Lapedes, A., Hahn, B. H., Wolinsky, S., & Bhattacharya, T. (2000) · Science · doi:10.1126/science.288.5472.1789 · Cited by 1,021
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Condra, J. H., Schleif, W. A., Blahy, O. M., Gabryelski, L. J., Graham, D. J., Quintero, J., Rhodes, A., Robbins, H. L., Roth, E., Shivaprakash, M., et al. (1995) · Nature · doi:10.1038/374569a0 · Cited by 974
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database
Shafer, R. W., Stevenson, D., & Chan, B. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.348 · Cited by 907
Self-citationHirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Molla, A., Korneyeva, M., Gao, Q., Vasavanonda, S., Schipper, P. J., Mo, H.-M., Markowitz, M., Chernyavskiy, T., Niu, P., Lyons, N., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-760 · Cited by 762
Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial
Durant, J., Clevenbergh, P. A., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J., & Dellamonica, P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12291-2 · Cited by 752
Resistance to ddI and Sensitivity to AZT Induced by a Mutation in HIV-1 Reverse Transcriptase
St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavro, C. L., King, D. M., Kellam, P., Kemp, S. D., & Larder, B. A. (1991) · Science · doi:10.1126/science.1716788 · Cited by 679
Deeks, S. G., Wrin, T., Liegler, T., Hoh, R., Hayden, M., Barbour, J. D., Hellmann, N. S., Petropoulos, C. J., McCune, J. M., Hellerstein, M. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102153440702 · Cited by 653
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y., Wrin, T., Huang, W., Tian, H., Smith, D., Winslow, G. A., Capon, D. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.920-928.2000 · Cited by 646
Potential Mechanism for Sustained Antiretroviral Efficacy of AZT-3TC Combination Therapy
Larder, B. A., Kemp, S. D., & Harrigan, P. R. (1995) · Science · doi:10.1126/science.7542804 · Cited by 623
Tisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Eron, J. J., Benoit, S. L., Jemsek, J., MacArthur, R. D., Santana, J., Quinn, J. B., Kuritzkes, D. R., Fallon, M. A., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332502 · Cited by 531
Mechanism of Inhibition of HIV-1 Reverse Transcriptase by Nonnucleoside Inhibitors
Spence, R. A., Kati, W. M., Anderson, K. S., & Johnson, K. A. (1995) · Science · doi:10.1126/science.7532321 · Cited by 522
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S. A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1411 · Cited by 503
Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A., Mannheimer, S., Thompson, M., Abrams, D. I., Brizz, B., et al. (2000) · AIDS · doi:10.1097/00002030-200006160-00001 · Cited by 494
Young, S. D., Britcher, S. F., Tran, L. O., Payne, L. S., Lumma, W. C., Lyle, T. A., Huff, J. R., Anderson, P. S., Olsen, D. B., & Carroll, S. S. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2602 · Cited by 482
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
Chan, D. C., Chutkowski, C. T., & Kim, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15613 · Cited by 477
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3218 · Cited by 471
HIV-1 Drug Resistance in Newly Infected Individuals
Boden, D. (1999) · JAMA · doi:10.1001/jama.282.12.1135 · Cited by 466
Hecht, F. M., Grant, R. M., Petropoulos, C. J., Dillon, B., Chesney, M. A., Tian, H., Hellmann, N. S., Bandrapalli, N. I., Digilio, L., Branson, B., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390504 · Cited by 444
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors
Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D., & Stuart, D. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-303 · Cited by 442
Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., & Kim, P. S. (1999) · Cell · doi:10.1016/s0092-8674(00)80066-5 · Cited by 442
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
Rimsky, L. T., Shugars, D. C., & Matthews, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.986-993.1998 · Cited by 423
Kellam, P., Boucher, C. A., & Larder, B. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1934 · Cited by 413
Back, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., van Kuilenburg, A. B., van Gennip, A. H., & Berkhout, B. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00777.x · Cited by 406
Condra, J. H., Holder, D. J., Schleif, W. A., Blahy, O. M., Danovich, R. M., Gabryelski, L. J., Graham, D. J., Laird, D., Quintero, J. C., Rhodes, A., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.12.8270-8276.1996 · Cited by 405
Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1
Martinez-Picado, J., Savara, A. V., Sutton, L., & D’Aquila, R. T. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3744-3752.1999 · Cited by 396
Transmission of antiretroviral-drug-resistant HIV-1 variants
Yerly, S., Kaiser, L., Race, E., Bru, J.-P., Clavel, F., & Perrin, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12262-6 · Cited by 389
Hertogs, K., de Béthune, M.-P., Miller, V., Ivens, T., Schel, P., Van Cauwenberge, A., Van den Eynde, C., van Gerwen, V., Azijn, H., van Houtte, M., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.269 · Cited by 389
Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L., Chokekijchai, S., Roy, B. M., Arnold, E., & Yarchoan, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.6.2398 · Cited by 386
The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.
Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S., Hellmig, B., Woolf, D. J., Debouck, C., & Harrison, S. C. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.4.1222 · Cited by 378
Nijhuis, M., Schuurman, R., de Jong, D., Erickson, J., Gustchina, E., Albert, J., Schipper, P., Gulnik, S., & Boucher, C. A. B. (1999) · AIDS · doi:10.1097/00002030-199912030-00006 · Cited by 367
Descamps, D. (2000) · JAMA · doi:10.1001/jama.283.2.205 · Cited by 367
Boucher, C. A. B., O'Sullivan, E., Mulder, J. W., Ramautarsing, C., Kellam, P., Darby, G., Lange, J. M. A., Goudsmit, J., & Larder, B. A. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/165.1.105 · Cited by 352
Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G., & Scott, W. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80185-9 · Cited by 349
Arion, D., Kaushik, N., McCormick, S., Borkow, G., & Parniak, M. A. (1998) · Biochemistry · doi:10.1021/bi981200e · Cited by 345
Reduced Antiretroviral Drug Susceptibility Among Patients With Primary HIV Infection
Little, S. J. (1999) · JAMA · doi:10.1001/jama.282.12.1142 · Cited by 335
DeGruttola, V., Dix, L., D'Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., et al. (2000) · Antiviral Therapy · doi:10.1177/135965350000500112 · Cited by 326
Zhang, Y. M., Imamichi, H., Imamichi, T., Lane, H. C., Falloon, J., Vasudevachari, M. B., & Salzman, N. P. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6662-6670.1997 · Cited by 320
Boucher, C. A., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M. A., & Cameron, J. M. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.10.2231 · Cited by 313
Sarafianos, S. G., Das, K., Clark, A. D., Ding, J., Boyer, P. L., Hughes, S. H., & Arnold, E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10027 · Cited by 309
Havlir, D. V., Marschner, I. C., Hirsch, M. S., Collier, A. C., Tebas, P., Bassett, R. L., Ioannidis, J. P. A., Holohan, M. K., Leavitt, R., Boone, G., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391801 · Cited by 307
Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase
Wainberg, M. A., Drosopoulos, W. C., Salomon, H., Hsu, M., Borkow, G., Parniak, M. A., Gu, Z., Song, Q., Manne, J., Islam, S., et al. (1996) · Science · doi:10.1126/science.271.5253.1282 · Cited by 304
Meyer, P. R., Matsuura, S. E., So, A. G., & Scott, W. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13471 · Cited by 298
Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
The Effect of High-Dose Saquinavir on Viral Load and CD4+ T-Cell Counts in HIV-Infected Patients
Schapiro, J. M., Winters, M. A., Stewart, F., Efron, B., Norris, J., Kozal, M. J., & Merigan, T. C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-12-199606150-00003 · Cited by 296
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
Doyon, L., Croteau, G., Thibeault, D., Poulin, F., Pilote, L., & Lamarre, D. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3763-3769.1996 · Cited by 295
Mutations in Retroviral Genes Associated with Drug Resistance
Mellors, J. W., Schinazi, R. F., & Larder, B. A. (1996) · Cited by 285
Bacheler, L. T., Anton, E. D., Kudish, P., Baker, D., Bunville, J., Krakowski, K., Bolling, L., Aujay, M., Wang, X. V., Ellis, D., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2475-2484.2000 · Cited by 268
HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers
Kaul, R., Trabattoni, D., Bwayo, J. J., Arienti, D., Zagliani, A., Mwangi, F. M., Kariuki, C., Ngugi, E. N., MacDonald, K. S., Ball, T. B., et al. (1999) · AIDS · doi:10.1097/00002030-199901140-00004 · Cited by 267
Mammano, F., Petit, C., & Clavel, F. (1998) · Journal of Virology · doi:10.1128/jvi.72.9.7632-7637.1998 · Cited by 264
Selective Excision of AZTMP by Drug-Resistant Human Immunodeficiency Virus Reverse Transcriptase
Boyer, P. L., Sarafianos, S. G., Arnold, E., & Hughes, S. H. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4832-4842.2001 · Cited by 264
Gulnik, S. V., Suvorov, L. I., Liu, B., Yu, B., Anderson, B., Mitsuya, H., & Erickson, J. W. (1995) · Biochemistry · doi:10.1021/bi00029a002 · Cited by 260
In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA
Wainberg, M. A., Miller, M. D., Quan, Y., Salomon, H., Mulato, A. S., Lamy, P. D., Margot, N. A., Anton, K. E., & Cherrington, J. M. (1999) · Antiviral Therapy · doi:10.1177/135965359900400205 · Cited by 247
Iversen, A. K., Shafer, R. W., Wehrly, K., Winters, M. A., Mullins, J. I., Chesebro, B., & Merigan, T. C. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.1086-1090.1996 · Cited by 245
Self-citationBacheler, L. T., Jeffrey, S., Hanna, G. J., D’Aquila, R. T., Wallace, L., Logue, K. A., Cordova, B. C., Hertogs, K., Larder, B. A., Buckery, R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.4999-5008.2001 · Cited by 234
Stuyver, L., Wyseur, A., Rombout, A., Louwagie, J., Scarcez, T., Verhofstede, C., Rimland, D., Schinazi, R. F., & Rossau, R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.2.284 · Cited by 234
Gao, W. Y., Shirasaka, T., Johns, D. G., Broder, S., & Mitsuya, H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116463 · Cited by 231
Gu, Z., Gao, Q., Li, X., Parniak, M. A., & Wainberg, M. A. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.7128-7135.1992 · Cited by 228
Larder, B. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2664 · Cited by 228
Zolopa, A. R., Shafer, R. W., Warford, A. L., Montoya, J. G., Hsu, P., Katzenstein, D. A., Merigan, T. C., & Efron, B. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-11-199912070-00003 · Cited by 225
Self-citationTisdale, M., Alnadaf, T., & Cousens, D. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1094 · Cited by 223
Production of resistant HIV mutants during antiretroviral therapy
Ribeiro, R. M., & Bonhoeffer, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7681 · Cited by 220
Winters, M. A., Coolley, K. L., Girard, Y. A., Levee, D. J., Hamdan, H., Shafer, R. W., Katzenstein, D. A., & Merigan, T. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4948 · Cited by 216
Self-citationHermankova, M. (2001) · JAMA · doi:10.1001/jama.286.2.196 · Cited by 216
Cingolani, A., Antinori, A., Rizzo, M. G., Murri, R., Ammassari, A., Baldini, F., Di Giambenedetto, S., Cauda, R., & De Luca, A. (2002) · AIDS · doi:10.1097/00002030-200202150-00008 · Cited by 214
Patick, A. K., Duran, M., Cao, Y., Shugarts, D., Keller, M., Mazabel, E., Knowles, M. R., Chapman, S., Kuritzkes, D. R., & Markowitz, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2637 · Cited by 214
Ho, D. D., Toyoshima, T., Mo, H., Kempf, D. J., Norbeck, D., Chen, C. M., Wideburg, N. E., Burt, S. K., Erickson, J. W., & Singh, M. K. (1994) · Journal of Virology · doi:10.1128/jvi.68.3.2016-2020.1994 · Cited by 212
Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M. A., Goldberg, E., Cameron, J., & Wainberg, M. A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.2.275 · Cited by 211
Antiretroviral resistance during successful therapy of HIV type 1 infection
Martinez-Picado, J., DePasquale, M. P., Kartsonis, N., Hanna, G. J., Wong, J., Finzi, D., Rosenberg, E., Günthard, H. F., Sutton, L., Savara, A., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.20.10948 · Cited by 209
Patick, A. K., Mo, H., Markowitz, M., Appelt, K., Wu, B., Musick, L., Kalish, V, Kaldor, S., Reich, S., Ho, D., et al. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.2.292 · Cited by 209
Jackson, J. B., Becker-Pergola, G., Guay, L. A., Musoke, P., Mracna, M., Fowler, M. G., Mofenson, L. M., Mirochnick, M., Mmiro, F., & Eshleman, S. H. (2000) · AIDS · doi:10.1097/00002030-200007280-00001 · Cited by 208
Shafer, R. W., Kozal, M. J., Winters, M. A., Iversen, A. K. N., Katzenstein, D. A., Ragni, M. V., Meyer, W. A., Gupta, P., Rasheed, S., Coombs, R., et al. (1994) · Journal of Infectious Diseases · doi:10.1093/infdis/169.4.722 · Cited by 205
Self-citation3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine
Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Meibohm, A., Condra, J. H., Valentine, F. T., McMahon, D., Gonzalez, C., Jonas, L., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00007 · Cited by 204
Brown, A. J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1862 · Cited by 201
Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing
Larder, B. A., Kohli, A., Kellam, P., Kemp, S. D., Kronick, M., & Henfrey, R. D. (1993) · Nature · doi:10.1038/365671a0 · Cited by 198
Robinson, B. S., Riccardi, K. A., Gong, Y.-F., Guo, Q., Stock, D. A., Blair, W. S., Terry, B. J., Deminie, C. A., Djang, F., Colonno, R. J., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2093-2099.2000 · Cited by 198
Simmonds, P., Zhang, L. Q., McOmish, F., Balfe, P., Ludlam, C. A., & Brown, A. J. (1991) · Journal of Virology · doi:10.1128/jvi.65.11.6266-6276.1991 · Cited by 198
Shafer, R. W., Winters, M. A., Palmer, S., & Merigan, T. C. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-11-199806010-00008 · Cited by 197
Self-citationThe Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance
Hsiou, Y., Ding, J., Das, K., Clark, A. D., Boyer, P. L., Lewi, P., Janssen, P. A. J., Kleim, J.-P., Rösner, M., Hughes, S. H., et al. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4648 · Cited by 195
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy
Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S., Nadler, J., Verbiest, W., Hertogs, K., Ames, M., et al. (2002) · AIDS · doi:10.1097/00002030-200203080-00009 · Cited by 195
Fitzgibbon, J. E., Howell, R. M., Haberzettl, C. A., Sperber, S. J., Gocke, D. J., & Dubin, D. T. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.1.153 · Cited by 194
Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors
Boden, D., & Markowitz, M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2775 · Cited by 191
Havlir, D. V., Eastman, S., Gamst, A., & Richman, D. D. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.7894-7899.1996 · Cited by 191
Jacobsen, H., Yasargil, K., Winslow, D. L., Craig, J. C., Kröhn, A., Duncan, I. B., & Mous, J. (1995) · Virology · doi:10.1016/s0042-6822(95)80069-7 · Cited by 190
Tisdale, M., Myers, R. E., Maschera, B., Parry, N. R., Oliver, N. M., & Blair, E. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.8.1704 · Cited by 180
Partaledis, J. A., Yamaguchi, K., Tisdale, M., Blair, E. E., Falcione, C., Maschera, B., Myers, R. E., Pazhanisamy, S., Futer, O., & Cullinan, A. B. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5228-5235.1995 · Cited by 180
Kuritzkes, D. R., Quinn, J. B., Benoit, S. L., Shugarts, D. L., Griffin, A., Bakhtiari, M., Poticha, D., Eron, J. J., Fallon, M. A., & Rubin, M. (1996) · AIDS · doi:10.1097/00002030-199610090-00007 · Cited by 177
Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance (2001) · BMJ · doi:10.1136/bmj.322.7294.1087 · Cited by 175
Chen, Z., Li, Y., Chen, E., Hall, D. L., Darke, P. L., Culberson, C., Shafer, J. A., & Kuo, L. C. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47199-2 · Cited by 172
Götte, M., Arion, D., Parniak, M. A., & Wainberg, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3579-3585.2000 · Cited by 172
Larder, B. A. (1994) · Journal of General Virology · doi:10.1099/0022-1317-75-5-951 · Cited by 166
Cornelissen, M., van den Burg, R., Zorgdrager, F., Lukashov, V, & Goudsmit, J. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6348-6358.1997 · Cited by 165
Frost, S. D. W., Nijhuis, M., Schuurman, R., Boucher, C. A. B., & Brown, A. J. L. (2000) · Journal of Virology · doi:10.1128/jvi.74.14.6262-6268.2000 · Cited by 161
Baldwin, E. T., Bhat, T. N., Gulnik, S., Liu, B., Topol, I. A., Kiso, Y., Mimoto, T., Mitsuya, H., & Erickson, J. W. (1995) · Structure · doi:10.1016/s0969-2126(01)00192-7 · Cited by 160
Harrigan, P. R., Stone, C., Griffin, P., Nájera, I., Bloor, S., Kemp, S., Tisdale, M., Larder, B., & the CNA2001 Investigative Group (2000) · The Journal of Infectious Diseases · doi:10.1086/315317 · Cited by 159
Piketty, C., Weiss, L., Thomas, F., Mohamed, A. S., Belec, L., & Kazatchkine, M. D. (2001) · The Journal of Infectious Diseases · doi:10.1086/319861 · Cited by 158
Tebas, P., Patick, A. K., Kane, E. M., Klebert, M. K., Simpson, J. H., Erice, A., Powderly, W. G., & Henry, K. (1999) · AIDS · doi:10.1097/00002030-199902040-00002 · Cited by 158
Retrovirus mutation rates and their role in genetic variation.
Mansky, L. M. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-6-1337 · Cited by 157
Delassus, S., Cheynier, R., & Wain–Hobson, S. (1991) · Journal of Virology · doi:10.1128/jvi.65.1.225-231.1991 · Cited by 155
Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro
Larder, B. A., Kellam, P., & Kemp, S. D. (1993) · Nature · doi:10.1038/365451a0 · Cited by 153
Markowitz, M. H., Conant, M. A., Hurley, A., Schluger, R., Duran, M., Peterkin, J. J., Chapman, S., Patick, A. K., Hendricks, A., Yuen, G. J., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/515312 · Cited by 153
Keulen, W., Back, N. K. T., van Wijk, A., Boucher, C. A., & Berkhout, B. (1997) · Journal of Virology · doi:10.1128/jvi.71.4.3346-3350.1997 · Cited by 152
Günthard, H. F., Wong, J. K., Ignacio, C. C., Havlir, D. V., & Richman, D. D. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.869 · Cited by 150
Kusumi, K., Conway, B. R., Cunningham, S., et al. (1992) · Journal of Virology · doi:10.1128/jvi.66.2.875-885.1992 · Cited by 147
Winters, M. A., Shafer, R. W., Jellinger, R. A., Mamtora, G., Gingeras, T., & Merigan, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.757 · Cited by 147
Self-citationPieniążek, D., Rayfield, M. A., Hu, D. J., Nkengasong, J. N., Wiktor, S. Z., Downing, R. G., Biryahwaho, B., Mastro, T. D., Tanuri, A., Soriano, V., et al. (2000) · AIDS · doi:10.1097/00002030-200007280-00004 · Cited by 145
Nonnucleoside Reverse Transcriptase Inhibitor Resistance
Deeks, S. G. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200103011-00004 · Cited by 145
Shirasaka, T., Yarchoan, R., O'Brien, M. C., Husson, R. N., Anderson, B. D., Kojima, E., Shimada, T., Broder, S., & Mitsuya, H. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.562 · Cited by 139
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus
Stoddart, C. A., Liegler, T. J., Mammano, F., Linquist-Stepps, V. D., Hayden, M. S., Deeks, S. G., Grant, R. M., Clavel, F., & McCune, J. M. (2001) · Nature Medicine · doi:10.1038/89090 · Cited by 136
Mahalingam, B., Louis, J. M., Hung, J., Harrison, R. W., & Weber, I. T. (2001) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.1057 · Cited by 135
de Ronde, A., van Dooren, M., van der Hoek, L., Bouwhuis, D., de Rooij, E., van Gemen, B., de Boer, R. J., & Goudsmit, J. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.595-602.2001 · Cited by 135
Structural and kinetic analysis of drug resistant mutants of HIV‐1 protease
Mahalingam, B., Louis, J. M., Reed, C. C., Adomat, J. M., Krouse, J., Wang, Y., Harrison, R. W., & Weber, I. T. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00514.x · Cited by 133
Kemp, S. D., Shi, C., Bloor, S., Harrigan, P. R., Mellors, J. W., & Larder, B. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5093-5098.1998 · Cited by 133
Miller, V., Ait‐Khaled, M., Stone, C., Griffin, P. C., Mesogiti, D., Cutrell, A. G., Harrigan, R., Staszewski, S., Katlama, C., Pearce, G. L., et al. (2000) · AIDS · doi:10.1097/00002030-200001280-00012 · Cited by 132
Kozal, M. J., Shafer, R. W., Winters, M. A., Katzenstein, D. A., & Merigan, T. C. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.3.526 · Cited by 132
Self-citationRace, E., Dam, E. M., Obry, V., Paulous, S., & Clavel, F. (1999) · AIDS · doi:10.1097/00002030-199910220-00008 · Cited by 131
Côté, H. C. F., Brumme, Z. L., & Harrigan, P. R. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.589-594.2001 · Cited by 131
Sarafianos, S. G., Das, K., Dingi, J., Boyer, P. L., Hughes, S. H., & Arnold, E. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80071-4 · Cited by 130
Goudsmit, J., de Ronde, A., de Rooij, E., & de Boer, R. J. (1997) · Journal of Virology · doi:10.1128/jvi.71.6.4479-4484.1997 · Cited by 129
Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV Infection
Albrecht, M., Bosch, R. J., Hammer, S. M., Liou, S.-H., Kessler, H. A., Para, M. F., Eron, J. J., Valdez, H., Dehlinger, M., & Katzenstein, D. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450602 · Cited by 127
Perno, C. F., Cozzi‐Lepri, A., Balotta, C., Forbici, F., Violin, M., Bertoli, A., Facchi, G., Pezzotti, P., Cadeo, G., Tositti, G., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/323604 · Cited by 124
S-1153 Inhibits Replication of Known Drug-Resistant Strains of Human Immunodeficiency Virus Type 1
Fujiwara, T., Sato, A., El‐Farrash, M. A., Miki, S., Abe, K., Isaka, Y., Kodama, M., Wu, Y., Chen, L. B., Harada, H., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.6.1340 · Cited by 123
Yahi, N., Tamalet, C., Tourrès, C., Tivoli, N., Ariasi, F., Volot, F., Gastaut, J., Gallais, H., Moreau, J., & Fantini, J. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.12.4099-4106.1999 · Cited by 123
Linkage disequilibrium test implies a large effective population number for HIV in vivo
Rouzine, I. M., & Coffin, J. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10758 · Cited by 123
Harrigan, P. R., Kinghorn, I., Bloor, S., Kemp, S. D., Nájera, I., Kohli, A., & Larder, B. A. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.5930-5934.1996 · Cited by 119
Hanna, G. J., Johnson, V. A., Kuritzkes, D. R., Richman, D. D., Brown, A., Savara, A. V., Hazelwood, J. D., & D’Aquila, R. T. (2000) · The Journal of Infectious Diseases · doi:10.1086/315329 · Cited by 118
Imamichi, H., Crandall, K. A., Natarajan, V., Jiang, M., Dewar, R. L., Berg, S. C., Gaddam, A., Bosche, M. C., Metcalf, J. A., Davey, R. T., et al. (2001) · The Journal of Infectious Diseases · doi:10.1086/317641 · Cited by 117
Rose, R. E., Gong, Y., Greytok, J. A., Bechtold, C. M., Terry, B., Robinson, B. S., Alam, M., Colonno, R. J., & Lin, P. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.4.1648 · Cited by 116
Pluda, J. M., Cooley, T. P., Montaner, J. S. G., Shay, L. E., Reinhalter, N. E., Warthan, S. N., Ruedy, J., Hirst, H. M., Vicary, C., QUINN, J., et al. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1438 · Cited by 116
Hertogs, K., Bloor, S., Vroey, V. D., den Eynde, C. V., Dehertogh, P., Cauwenberge, A. V., Stürmer, M., Alcorn, T. M., Wegner, S. A., Houtte, M. V., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.568-573.2000 · Cited by 116
Goudsmit, J., de Ronde, A., Ho, D. D., & Perelson, A. S. (1996) · Journal of Virology · doi:10.1128/jvi.70.8.5662-5664.1996 · Cited by 115
Richman, D. D., Guatelli, J. C., Grimes, J. M., Tsiatis, A. A., & Gingeras, T. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.6.1075 · Cited by 114
Hooker, D. J., Tachedjian, G., Solomon, A. E., Gurusinghe, A. D., Land, S., Birch, C. J., Anderson, J. L., Roy, B. M., Arnold, E., & Deacon, N. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8010-8018.1996 · Cited by 114
Boyer, P. L., & Hughes, S. H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1624 · Cited by 113
Miller, V., & Larder, B. A. (2001) · Antiviral Therapy · doi:10.1177/135965350100603s03 · Cited by 110
HIV-1: Gambling on the evolution of drug resistance?
Brown, A., & Richman, D. D. (1997) · Nature Medicine · doi:10.1038/nm0397-268 · Cited by 110
Sharma, P. L., & Crumpacker, C. S. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8448-8456.1999 · Cited by 109
Archer, R. H., Dykes, C., Gerondelis, P., Lloyd, A. L., Fay, P. J., Reichman, R. C., Bambara, R. A., & Demeter, L. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8390-8401.2000 · Cited by 109
Meyer, P. R., Matsuura, S. E., Schinazi, R. F., So, A. G., & Scott, W. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3465-3472.2000 · Cited by 108
Byrnes, V. W., Sardana, V. V., Schleif, W. A., Condra, J. H., Waterbury, J. A., Wolfgang, J., Long, W. J., Schneider, C. L., Schlabach, A. J., & Wolanski, B. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.8.1576 · Cited by 106
Pellegrin, I., Izopet, J., Reynes, J., Denayrolles, M., Montès, B., Pellegrin, J., Massip, P., & Puel, J. (1999) · AIDS · doi:10.1097/00002030-199909100-00014 · Cited by 106
Palmer, S., Alaeus, A., Albert, J., & COX, S. (1998) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1998.14.157 · Cited by 105
Back, N. K. T., van Wijk, A., Remmerswaal, D., van Monfort, M., Nijhuis, M., Schuurman, R., & Boucher, C. A. (2000) · AIDS · doi:10.1097/00002030-200001070-00019 · Cited by 105
Duwe, S. C., Brunn, M., Altmann, D., Hamouda, O., Schmidt, B., Walter, H., Pauli, G., & cherer, C. K. ⁄. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200103010-00010 · Cited by 105
Managing Resistance to Anti-HIV Drugs: An Important Consideration for Effective Disease Management
Vandamme, A., Laethem, K. V., & Clercq, E. D. (1999) · Drugs · doi:10.2165/00003495-199957030-00006 · Cited by 103
Sharma, P., & Crumpacker, C. S. (1997) · Journal of Virology · doi:10.1128/jvi.71.11.8846-8851.1997 · Cited by 103
Shih, C. K., Rose, J. M., Hansen, G. L., Wu, J. C., Bacolla, A., & Griffin, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.21.9878 · Cited by 102
Caliendo, A. M., Savara, A. V., An, D., Devore, K. M., Kaplan, J. C., & D’Aquila, R. T. (1996) · Journal of Virology · doi:10.1128/jvi.70.4.2146-2153.1996 · Cited by 102
Schuurman, R., Brambilla, D. J., de Groot, T. M., Huang, D., Land, S., Bremer, J. W., Benders, I., & Boucher, C. A. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202753472801 · Cited by 101
Winters, M. A., Schapiro, J., Lawrence, J., & Merigan, T. C. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5303-5306.1998 · Cited by 100
de Jong, J. J., Goudsmit, J., Lukashov, V. V., Hillebrand, M. E., Baan, E., Huismans, R., Danner, S. A., ten Veen, J. H., de Wolf, F., & Jurriaans, S. (1999) · AIDS · doi:10.1097/00002030-199901140-00010 · Cited by 100
Resistance to Protease Inhibitors
Miller, V. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200103011-00005 · Cited by 98
Nucleotide-Induced Stable Complex Formation by HIV-1 Reverse Transcriptase
Tong, W., Lu, C., Sharma, S. K., Matsuura, S. E., So, A. G., & Scott, W. A. (1997) · Biochemistry · doi:10.1021/bi962410z · Cited by 97
Ala, P. J., Huston, E. E., Klabe, R. M., McCabe, D. D., Duke, J. L., Rizzo, C. J., Korant, B. D., DeLoskey, R. J., Lam, P. Y. S., Hodge, C. N., et al. (1997) · Biochemistry · doi:10.1021/bi962234u · Cited by 97
de Jong, M. D., Veenstra, J., Stilianakis, N. I., Schuurman, R., Lange, J. M. A., de Boer, R. J., & Boucher, C. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.11.5501 · Cited by 96
Vaerenbergh, K. V., Laethem, K. V., Albert, J., Boucher, C. A., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C. H., Pannecouque, C. C., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.8.2109-2117.2000 · Cited by 94
Casado, J. L., Hertogs, K., Ruiz, L., Dronda, F., Cauwenberge, A. V., Arnó, A., García-Arata, I., Bloor, S., Bonjoch, A., Blázquez, J., et al. (2000) · AIDS · doi:10.1097/00002030-200001280-00001 · Cited by 92
Naeger, L. K., Margot, N., & Miller, M. D. (2001) · Antiviral Therapy · doi:10.1177/135965350100600205 · Cited by 92
Kantor, R., Machekano, R., Gonzales, M. J., Dupnik, K., Schapiro, J. M., & Shafer, R. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.296 · Cited by 91
Self-citationKleim, J. P., Rösner, M., Winkler, I., Paessens, A., Kirsch, R., Hsiou, Y., Arnold, E., & Riess, G. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.34 · Cited by 90
Nonnucleoside Reverse Transcriptase Inhibitor Resistance
Deeks, S. G. (2001) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200103011-00004 · Cited by 90
Rusconi, S., Catamancio, S. L. S., Citterio, P., Kurtagic, S., Violin, M., Balotta, C., Moroni, M., Galli, M., & Monforte, A. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.5.1328-1332.2000 · Cited by 89
Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden‐Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., & Reichman, R. C. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.794-797.2000 · Cited by 89
Self-citationWilson, J. W., Bean, P., Robins, T. S., Graziano, F. M., & Persing, D. H. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.8.3022-3028.2000 · Cited by 89
Hizi, A., Tal, R., Shaharabany, M., Currens, M. J., Boyd, M. R., Hughes, S. H., & McMahon, J. B. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1037 · Cited by 88
Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase
Essink, B. B. O., Back, N. K., & Berkhout, B. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.16.3212 · Cited by 88
Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects
Little, S. J. (2000) · Antiviral Therapy · doi:10.1177/135965350000500111 · Cited by 87
Gerondelis, P., Archer, R. H., Palaniappan, C., Reichman, R. C., Fay, P. J., Bambara, R. A., & Demeter, L. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5803-5813.1999 · Cited by 86
Fidelity of HIV-1 Reverse Transcriptase Copying a Hypervariable Region of the HIV-1 env Gene
Ji, J. J., & Loeb, L. A. (1994) · Virology · doi:10.1006/viro.1994.1130 · Cited by 85
Schmit, J., Laethem, K. V., Ruiz, L., Hermans, P., Sprecher, S., Sönnerborg, A. B., Leal, M., Harrer, T., Clotet, B., Arendt, V., et al. (1998) · AIDS · doi:10.1097/00002030-199815000-00012 · Cited by 84
Imamichi, T., Berg, S. C., Imamichi, H., Lopez, J. C., Metcalf, J. A., Falloon, J., & Lane, H. C. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.10958-10964.2000 · Cited by 83
POLYGENIC AND MULTIFACTORIAL DISEASE GENE ASSOCIATION IN MAN: Lessons from AIDS
O’Brien, S. J., Nelson, G. W., Winkler, C. A., & Smith, M. W. (2000) · Annual Review of Genetics · doi:10.1146/annurev.genet.34.1.563 · Cited by 81
Sevin, A. D., DeGruttola, V. G., Nijhuis, M., Schapiro, J., Foulkes, A. S., Para, M. F., & Boucher, C. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315673 · Cited by 80
Shulman, N. S., Zolopa, A. R., Passaro, D., Shafer, R. W., Huang, W., Katzenstein, D. A., Israelski, D. M., Hellmann, N., Petropoulos, C., & Whitcomb, J. M. (2001) · AIDS · doi:10.1097/00002030-200106150-00007 · Cited by 78
Self-citationGu, Z., Arts, E. J., Parniak, M. A., & Wainberg, M. A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2760 · Cited by 76
Kohlstaedt, L. A., & Steitz, T. A. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.20.9652 · Cited by 73
Ren, J., Esnouf, R. M., Hopkins, A. L., Jones, E. Y., Kirby, I., Keeling, J., Ross, C., Larder, B. A., Stuart, D. I., & STAMMERS, D. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9518 · Cited by 72
Shah, F. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002881200 · Cited by 72
Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors
Olsen, D. B., Stahlhut, M. W., Rutkowski, C. A., Schock, H. B., vanOlden, A. L., & Kuo, L. C. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.23699 · Cited by 71
Lecossier, D., Bouchonnet, F., Schneider, P., Clavel, F., & Hance, A. J. (2001) · The Journal of Infectious Diseases · doi:10.1086/319285 · Cited by 71
Ayyavoo, V., Kudchodkar, S. B., Ramanathan, M. P., Le, P., Muthumani, K., Megalai, N. M., Dentchev, T., Santiago-Barrios, L., Mrinalini, C., & Weiner, D. B. (2000) · AIDS · doi:10.1097/00002030-200001070-00001 · Cited by 71
Back, N. K. T., & Berkhout, B. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2484 · Cited by 69
Kavlick, M. F., Wyvill, K. M., Yarchoan, R., & Mitsuya, H. (1998) · The Journal of Infectious Diseases · doi:10.1086/515324 · Cited by 69
Maguire, M. F., Gartland, M., Moore, S., Hill, A. M., Tisdale, M., Harrigan, R., & Kleim, J. (2000) · AIDS · doi:10.1097/00002030-200006160-00017 · Cited by 69
Gallego, O., de Mendoza, C., Pérez-Elías, M. J., Guardiola, J. M., Pedreira, J. D., Dalmau, D., González, J., Moreno, A. M., Arribas, J. R., Rubio, A., et al. (2001) · AIDS · doi:10.1097/00002030-200109070-00014 · Cited by 68
Shao, W., Everitt, L., Manchester, M., Loeb, D. D., Hutchison, C. A., & Swanstrom, R. I. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2243 · Cited by 67
Erali, M., Page, S. R., Reimer, L. G., & Hillyard, D. R. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.6.2157-2165.2001 · Cited by 67
Cited by
Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database
Shafer, R. W., Stevenson, D., & Chan, B. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.348 · Cited by 907
Self-citationHuman immunodeficiency virus reverse transcriptase and protease sequence database
Rhee, S.-Y. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg100 · Cited by 817
Sarrazin, C., Kieffer, T. L., Bartels, D., Hanzelka, B., Müh, U., Welker, M., Wincheringer, D., Zhou, Y., Chu, H., Lin, C., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.037 · Cited by 616
Wald, A., Huang, M., Carrell, D., Selke, S., & Corey, L. (2003) · The Journal of Infectious Diseases · doi:10.1086/379043 · Cited by 330
Twenty years of therapy for HIV-1 infection
Pomerantz, R. J., & Horn, D. L. (2003) · Nature Medicine · doi:10.1038/nm0703-867 · Cited by 284
Metadata
- Authors
- Shafer, R. W.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2002-04
- Volume
- 15
- Issue
- 2
- Pages
- 247-277
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2144729871
- Cited by
- 314
- References
- 238
- FWCI
- 17.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.